Timothy Shannon, MD, is a General Partner at Canaan Partners where he focuses on early stage biopharmaceutical companies. He is chairman of the board of Arvinas and Spyryx Therapeutics and is a director at IDEAYA, NextCure and Vivace. Prior successful companies include Civitas Theraputics (acquired by Acorda), Novira Therapeutics (acquired by Johnson & Johnson) and CytomX (CTMX, IPO 2015). Dr. Shannon previously was president and chief executive officer of CuraGen, a publically traded biopharmaceutical company. CuraGen merged with Celldex Therapeutics in 2009 where Dr. Shannon served on the board. Prior to that, he was senior vice president of global medical development for Bayer’s Pharmaceutical Business Group. Dr. Shannon began his career as an assistant professor of pulmonary and critical care medicine at Yale University School of Medicine, received his MD from the University of Connecticut, and his BA from Amherst College.